Cohorts, MET-01, Fall 2026.
Metabolic and Body Composition, Inaugural Cohort. Twelve weeks of structured study of metabolic peptides, mTOR, AMPK, GLP-1 pharmacology, and body composition protocols. Weekly live sessions with faculty, case review clinic every other week, cohort workspace for peer discussion.
Announced, enrollment opens in Phase 2. Runs 2026-10-05 through 2026-12-28, 12 weeks. Led by Sarah Liu, PhD , with Marcus Chen, MD.
Be notified when enrollment opens. Or request access to be notified.
At a Glance
- Code MET-01
- Length 12 weeks
- Seats 24 maximum, 24 remaining
- Price $2,400, illustrative
- Lead Sarah Liu, PhD
- Co-Lead Marcus Chen, MD
Curriculum
Twelve weeks, one topic per week. Case review clinic sessions are woven in on weeks 5, 8, and 12. The schedule is firm; topics may be refined based on the working cases in a given cohort.
- Wk 1 Metabolic pathways, orientation to the cohort model
- Wk 2 mTOR and AMPK, the central balance
- Wk 3 Mitochondrial biogenesis under peptide stimulation
- Wk 4 GLP-1 and dual agonists, receptor pharmacology
- Wk 5 Case review clinic, first session
- Wk 6 Insulin sensitivity, longitudinal markers
- Wk 7 Body composition, practical protocols
- Wk 8 Case review clinic, second session
- Wk 9 Hepatic and adipose tissue signaling
- Wk 10 Safety review, contraindications and interactions
- Wk 11 Integrative synthesis, patient across systems
- Wk 12 Final case review, cohort close
Scheduled Sessions
First sessions are confirmed and on the calendar. Remaining weeks are published closer to the cohort start.
Who This Is For
Practicing clinicians and scientists who want weekly faculty contact on a single therapeutic area, and who are willing to present anonymized cases for discussion. Not a primer. Comfort with the self-paced foundational material is assumed; a member can work through the public curriculum before applying.